COMMUNIQUÉS West-GlobeNewswire

Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
02/02/2026
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address [...]
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of [...]
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
02/02/2026
VANCOUVER, British Columbia, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6) (“Hydreight” or the “Company”), a provider of compliant digital health infrastructure and [...]
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute [...]
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
02/02/2026
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment [...]
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026
Industry’s Most Studied Placental Allografts Appear in Nearly 100 Clinical and Scientific Publications MARIETTA, Ga., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today [...]
DLH to Announce Fiscal 2026 First Quarter Financial Results
02/02/2026
ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital [...]
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
02/02/2026
58% of participants achieved a 75% improvement in Eczema Area and Severity Index (EASI-75) with ZORYVE cream 0.05% at Week 4 Investigational ZORYVE cream 0.05% was well tolerated and demonstrated a safety profile [...]
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
02/02/2026
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme TransportVehicle™ ( [...]
Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence
02/02/2026
Reinforcing AbinoNutra® NMN as a clinically validated, science-driven ingredient for NAD⁺ support and healthy longevity SHELTON, Conn., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Abinopharm, Inc. , a U.S.-based life-science [...]
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
02/02/2026
XanaMIA trial fully enrolled with final results expected in November 2026 SYDNEY, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the XanaMIA pivotal Alzheimer’s disease (AD) trial’ [...]
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
02/02/2026
UNIONDALE, NY, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (OTC: PRPH) (“ProPhase” or the “Company”) is pleased to invite investors to a webinar on Tuesday, February 3, 2026, at 4:15 p.m. ET. The exclusive [...]
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on structured teaching approaches and stable support environments. With the [...]
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026
Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative [...]
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026
REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
02/02/2026
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount [...]
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients [...]
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026
REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]

Pages